#JPM2021 #AdaptiveBiotech My Highlights: my interest lies in their angle on #LiquidBiopsy for #EarlyCancerDiagnostics, but they also deal with Life Science Research and Drug Discovery. 
Their T-Detect method is aiming at #MRD monitoring, here shown in a slide that relates it to their ImmunoSEQ T-MAP Cancer mapping tool, and their Identification of clinical TCR candidates.
They stress the T-cell Diagnostics angle in different slides. I recall only @freenome explicitly mentioning immune-profiling from the group of companies in early cancer diagnostics and #epigenomics profiling (Grail/GH/Thrive/Freenome/BioStar/CEGX/etc.)
"T-cells play a central role in the immune response to any disease". Very easy proposition to understand since #COVID19 has elevated T-cell response knowledge to new highs.
So much so that #COVID19 has displaced cancer detection in their T-Detect Gantt chart to only be present in their "Discovery" section. I am particularly keen to learn more about their #COVID19 T-cell Detect results in the future.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
